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ASK1 Expression, In Vivo Insulin Resistance, and Type 2
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Yunhua L. Muller, Sayuko Kobes, William C. Knowler, Leslie J. Baier, and Clifton Bogardus
OBJECTIVE—Prior genome-wide association and exon array
expression studies both provided suggestive evidence that apop-
tosis signal regulating kinase 1 (ASK1) may inﬂuence in vivo
insulin action in Pima Indians. Genetic variants in or near ASK1
were analyzed to assess the role of this gene in insulin action and
type 2 diabetes.
RESEARCH DESIGN AND METHODS—Genotypic data from
31 variants were used to determine the linkage disequilibrium
pattern across ASK1 in Pima Indians. Eight tag SNPs were
initially genotyped in 3,501 full-heritage Pima Indians. Replica-
tion for association with diabetes was assessed in a second
population-based sample of 3,723 Native Americans and the
published DIAGRAM study. Quantitative traits were analyzed in
536 nondiabetic Native Americans, and ASK1 expression was
examined in skeletal muscle of 153 nondiabetic Native
Americans.
RESULTS—Three tag SNPs were associated with type 2 diabe-
tes (rs35898099, P  0.003, odds ratio [95% CI] 1.27 [1.08–1.47];
rs1570056, P  0.007, 1.19 [1.05–1.36]; rs7775356, P  0.04, 1.14
[1.01–1.28]) in the full-heritage Pima Indians. The association
with rs35898099 was replicated in a second sample of Native
Americans (P  0.04, 1.22 [1.01–1.47]), while that for rs1570056
was replicated in the DIAGRAM study of Caucasians (Z statistic
based P  0.026; ﬁxed-effect model, 1.06 [1.00–1.12]). The
diabetes risk allele for rs1570056 was associated with reduced
insulin action as assessed by either HOMA-IR in 2,549 nondia-
betic full-heritage Pima Indians (P  0.027) or a hyperinsuline-
mic-euglycemic clamp among 536 nondiabetic Native Americans
(P  0.02). Real-time PCR identiﬁed a positive correlation
between ASK1 expression in skeletal muscle biopsies and in vivo
insulin action (P  0.02, r  0.23), and the risk allele for
rs1570056 was associated with lower ASK1 expression (P 
0.003, r  0.22).
CONCLUSIONS—ASK1 variants may increase susceptibility to
type 2 diabetes by decreasing insulin sensitivity via reduced
ASK1 expression. Diabetes 59:1276–1282, 2010
T
he Pima Indians of Arizona have an extremely
high prevalence of type 2 diabetes (1). Their
diabetes is characterized by obesity, decreased
insulin action (insulin resistance), impaired in-
sulin secretion, as well as increased endogenous glucose
production (2), and the ﬁrst three characteristics are
predictive of type 2 diabetes and heritable in this popula-
tion (3,4). To identify genetic variants that affect the
metabolic risk factors for diabetes, we previously com-
pleted a genome-wide association study (GWAS) in 536
metabolically phenotyped nondiabetic Native Americans
using the Affymetrix 100K Mapping Array (Bogardus et al.,
unpublished data) and also examined gene expression
proﬁles in skeletal muscle biopsies from nondiabetic Na-
tive Americans using an Affymetrix GeneChip Exon 1.0 ST
Array (Bogardus et al., unpublished data). The three traits
that predict type 2 diabetes, namely obesity, measures of
in vivo insulin action, and acute insulin secretion, were
investigated for association in these two preliminary stud-
ies. Genes associated with the same metabolic trait in both
of the two genome-wide studies (20 genes for each of the
three traits) were prioritized for further investigation. One
such prioritized gene is apoptosis signal regulating kinase
1( ASK1). Preliminary evidence from the GWAS suggested
that one intronic single nucleotide polymorphism (SNP) in
ASK1 (rs10484491) was associated with in vivo insulin
action, as determined by the hyperinsulinemic-euglycemic
clamp, and evidence from the exon array study suggested
that ASK1 expression levels were also correlated with in
vivo insulin action. Therefore, ASK1 was directly analyzed
as a candidate gene for type 2 diabetes in Pima Indians.
RESEARCH DESIGN AND METHODS
All subjects were part of our ongoing longitudinal study of the etiology of type
2 diabetes among the Gila River Indian Community in Arizona (1). Association
with type 2 diabetes was initially assessed in a population-based sample of
3,501 full-heritage Pima Indians. Among these individuals, 1,561 had been
diagnosed with type 2 diabetes and 1,940 were nondiabetic at the time of their
last exam. Replication for association with type 2 diabetes was assessed in a
second population-based sample of 3,723 subjects, most of whom were of
mixed-heritage (on average, their reported heritage was one-half Pima and
three-quarters American Indian). Among this replication sample, 750 subjects
had been diagnosed with type 2 diabetes and 2,973 individuals were nondia-
betic at their last exam. Homeostasis model assessment of insulin resistance
(HOMA-IR) was analyzed among 2,549 subjects of the full-heritage Pima
Indian sample who had available fasting plasma glucose and insulin data
measured from the last nondiabetic exam at age 15 years. Additionally, more
precise measures of diabetes-related quantitative traits were analyzed in 536
nondiabetic Native Americans who had also participated in our 100K GWAS of
pre-diabetic traits. ASK1 mRNA level was assessed using real-time PCR in
skeletal muscle biopsies provided by 153 nondiabetic Native Americans
involved in the exon array study, among whom 116 subjects had undergone a
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sensitivity during the same period for which the biopsy was ascertained.
Detailed characteristics of these sample sets are given in Table 1. All studies
were approved by the tribal council of the Gila River Indian Community and
the institutional review board of the National Institute of Diabetes and
Digestive and Kidney Diseases.
Metabolic phenotyping. A 75-g oral glucose tolerance test was used to
determine diabetes as deﬁned by the criteria of the World Health Organization
(5). HOMA-IR was calculated as fasting plasma glucose (mmol/l)  fasting
plasma insulin (U/ml)/22.5. Among subjects studied as inpatients, body
composition was estimated by underwater weighing or by total-body dual-
energy X-ray absorptiometry (DPX-1; Lunar Radiation) (6). The hyperinsuline-
mic-euglycemic clamp technique was used to determine insulin-stimulated
glucose disposal rate (7). Rates of endogenous glucose production basally and
during the clamp were measured using tritiated glucose as previously de-
scribed (7). The acute insulin response to a 25-g glucose bolus infusion was
calculated as previously described (7). Plasma free fatty acid concentrations
were measured using a colorimetric assay (Wako Chemicals).
Analysis of ASK1 expression levels in skeletal muscle. Percutaneous
needle biopsies were carried out on the vastus lateralis muscle under local
anesthesia with 1% lidocaine after a 12-h overnight fast, and the biopsy
specimens were immediately frozen in liquid nitrogen (8). Total RNA was
extracted using TRIzol reagent (Invitrogen, Carlsbad, CA) and was further
puriﬁed using a RNeasy Micro Kit (Qiagen, Valencia, CA). cDNA was synthe-
sized using a RETROscript Kit (Ambion, Austin, TX). ASK1 expression levels
were quantiﬁed using TaqMan real-time PCR with an ABI PRISM 7700 system
(Applied Biosystems, Foster City, CA) using the speciﬁc probe and primers for
ASK1 (assay ID: Hs00178726_m1; Applied Biosystems). Each sample was run
in triplicate and the ASK1 expression level was normalized to the mRNA level
of cyclophilin A (assay ID: Hs99999904_m1; Applied Biosystems). The relative
ASK1 expression level was determined by the Ct method according to the
manufacturer’s protocol (Applied Biosystems).
Sequencing and genotyping. Genotyping and quality-control methods for
the 100K GWAS for pre-diabetic traits were the same as previously described
for the 100K GWAS for type 2 diabetes (9). To identify novel variants in ASK1,
all exons, exon-intron boundaries, and 1.2 kb of the putative promoter region
were sequenced in 30 nondiabetic Pima Indians who were part of the prior
genome-wide exon array study. Sequencing was performed using the Big Dye
Terminator (Applied Biosystems) on an automated DNA capillary sequencer
(model 3730XL; Applied Biosystems). In addition to six variants identiﬁed by
sequencing and the SNP providing suggestive evidence for association with
insulin action in the prior GWAS, 24 additional database SNPs were directly
selected from NCBI dbSNP (Build 36) to provide a denser coverage of the
unsequenced intronic regions. The 24 dbSNPs spanned the entire ASK1 locus
with an inter-marker distance of 10  7 kb (mean  SD) and had an average
reported heterozygosity 10%. All these 31 SNPs were genotyped in 1,500
Pima Indians to determine the linkage disequilibrium (LD) pattern across
ASK1 and select tag SNPs. Genotyping was performed by SNPlex (Applied
Biosystems) after the manufacturer’s protocol.
Statistical analysis. Statistical analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, NC). The association of traits with genotype
was assessed with an additive model by assigning a numeric variable (0, 1, or
2) to the genotype based on the number of a given allele for each individual.
Logistic regression was used to assess the association of genotype with type
2 diabetes, whereas linear regression was used for analysis of continuous
variables. Both logistic and linear models were ﬁt with the generalized
estimating equation procedure to account for family membership and other
potential confounding variables (10). In the replication group, which included
many individuals of mixed heritage, the individual estimate of European
admixture was also used as a covariate; these estimates were derived by the
method of Hanis et al. (11) from 39 markers with large difference in allele
frequency between populations (12). A combined test of association with type
2 diabetes for the full-heritage and replication groups was conducted by the
inverse variance method (13). The LD pattern was evaluated by Haploview
(version 3.32). Tag SNPs were selected using the Tagger algorithm (14) among
those with a minor allele frequency 0.05 with a pairwise r
2 0.80 taken as
indicative of redundancy.
RESULTS
Sequencing of the exons, exon-intron boundaries, and
promoter region of ASK1 in 30 nondiabetic Pima Indians
identiﬁed six SNPs, none of which were novel (supplemen-
tary Table 1, available in an online appendix at http://
diabetes.diabetesjournals.org/cgi/content/full/db09-1700/DC1).
A total of 31 variants (six identiﬁed by sequencing, 1 from
the prior GWAS, and 24 selected from dbSNP; supplemen-
tary Table 1) were genotyped in 1,500 Pima Indians to
determine the LD structure across ASK1. All of these SNPs
were in the Hardy-Weinberg equilibrium, and eight tag
SNPs were then selected to capture all the common
variants (minor allele frequency 0.05) with a pairwise r
2
0.8 (Fig. 1).
The eight tag SNPs were initially genotyped in a popu-
lation-based sample of 3,501 full-heritage Pima Indians to
determine their association with type 2 diabetes (Table 2;
quality-control information provided in supplementary Ta-
ble 2). Three of the tag SNPs were signiﬁcantly associated
with type 2 diabetes (rs35898099, P  0.003, odds ratio
[95% CI] 1.27 [1.08–1.47]; rs1570056, P  0.007, 1.19
[1.05–1.36]; rs7775356, P  0.04, 1.14 [1.01–1.28)]; adjusted
for age, sex, and birth year; Table 2). These three SNPs
were further genotyped in a second population-based
sample of Native Americans (n  3,723). rs35898099 was
also nominally associated with type 2 diabetes in this
second sample (P  0.04, 1.22 [1.01–1.47], adjusted for age,
sex, birth year, and Pima heritage; Table 2). Analyzing the
combined samples (n  7,224) provided signiﬁcant asso-
ciations with type 2 diabetes (adjusted P  0.0004–0.04,
odds ratio 1.11–1.24; Table 2) for all three SNPs. To
determine if variants in this gene associate with type 2
diabetes in other ethnic groups, SNPs across ASK1 that
were analyzed in the DIAGRAM meta-analysis of Cauca-
sians (15) were examined. rs1570056 also showed nominal
association with type 2 diabetes in the DIAGRAM meta-
analysis (Z statistic based, P  0.027) and the risk allele is
consistent with the Pimas’ risk allele (ﬁxed-effect model,
TABLE 1
Characteristics of the sample sets used in this study
Sample set n
Full-heritage
Pimas
Non–full-
heritage
Pimas Diabetes status
Mean age
(years)
%
Male
Mean BMI
(kg/m
2)
Full-heritage Pima Indians 3,501 3,501 0 Diabetic (45%) 48.5  14.1 37 38.5  8.4
Nondiabetic 31.1  14.5 46 35.7  8.2
Native Americans 3,723 188 3,535 Diabetic (20%) 42.5  14.2 41 38.4  8.8
Nondiabetic 23.6  10.9 47 33.5  8.4
HOMA-IR analysis* 2,549 2,549 0 Nondiabetic 34.1  13.1 43 35.8  8.3
100K GWAS for pre-diabetic traits† 536 378 158 Nondiabetic 26.8  6.2 59 32.9  6.8
Muscle expression study‡ 153 98 55 Nondiabetic 29.4  7.2 70 32.7  6.4
Informative for in vivo insulin action§ 116 72 44 Nondiabetic 29.8  7.0 70 32.3  6.1
Data are means  SD unless otherwise indicated. *Subset of the full-heritage Pima Indian sample. †Subset of both the full-heritage Pima
Indian and Native American samples.
‡Subset of the subjects analyzed in the 100K GWAS. §Subset of the subjects with expression data.
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the C allele; Table 2). When the DIAGRAM results for
rs1570056 are combined with those from the Pima studies,
the summary odds ratio is 1.07 per copy of the C allele
(95% CI 1.02–1.13, P  0.008). rs35898099, which was
associated with type 2 diabetes in both Native American
samples, was not included in the DIAGRAM study or
HapMap CEU database. By sequencing 90 Caucasian sub-
jects, we ﬁnd that rs35898099 is also common in Cauca-
sians (minor allele A frequency  0.31); however, its
association with diabetes in this population remains to be
determined. We also performed a conditional analysis for
rs1570056 and rs35898099 to assess the possible relevance
between their associations with type 2 diabetes in Pima
studies. In the full-heritage Pima study, both of the SNPs
still showed signiﬁcant associations with type 2 diabetes
conditional on the effect of each other (P  0.037 and 0.02,
for rs1570056 and rs35898099, respectively), indicating
their effects on type 2 diabetes may be somewhat indepen-
dent in the full-heritage Pima population. However, when
the Native American sample was combined with the
full-heritage Pima sample, rs35898099 but not rs1570056
was signiﬁcantly associated with type 2 diabetes condi-
tional on the effect of the other SNP (P  0.001 for
rs35898099 conditional on rs1570056; P  0.268 for
rs1570056 conditional on rs35898099).
We further investigated whether the diabetes-associated
SNPs were associated with quantitative traits that predict
this disease. Among the full-heritage Pima Indians who
had available HOMA-IR information when they were non-
diabetic (n  2,549), rs1570056 was associated with
HOMA-IR, where individuals carrying the diabetes-risk
allele (C) were more insulin resistant (P  0.027, adjusted
for age, sex, and BMI; data not shown). The relationship
with insulin resistance was investigated further by analyz-
ing 536 nondiabetic Native Americans who had undergone
the hyperinsulinemic-euglycemic clamp, where subjects
carrying the diabetes risk allele (C) had decreased rates of
insulin-stimulated glucose disposal (P  0.02, adjusted for
age, sex, percent body fat, family membership, and Pima
heritage; Table 3). The association with insulin resistance
was also reﬂected by the increased plasma insulin levels
(adjusted P  0.04 for both fasting and 2-h insulin) during
an oral glucose tolerance test. In contrast, no signiﬁcant
difference in percent body fat or measure of acute insulin
secretion, by genotype of rs1570056, was observed (Table
3). Similarly, no signiﬁcant association with rates of en-
dogenous glucose production basally or during the clamp
was observed for rs1570056 (Table 3); this suggests that
ASK1 has no speciﬁc effect on hepatic insulin resistance.
Measures of fasting plasma free fatty acid concentration
were available on a small number (n  204) of individuals,
and the mean levels were comparable among the different
genotype groups for rs1570056 (P  0.91, data not shown).
To determine the potential mechanism whereby SNPs
within ASK1 inﬂuence insulin resistance and type 2 diabe-
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FIG. 1. Relative position and LD pattern of the 31 variants across the ASK1 locus in Pima Indians. LD is shown as r
2 and the eight tag SNPs (no.
1, 5, 7, 8, 9, 10, 20, and 31) were selected by Tagger algorithm (r
2 >0.8, minor allele frequency >0.05).
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tive real-time PCR in muscle cDNA isolated from 153
nondiabetic Native Americans. Adjusted for age, sex,
percent body fat, and Pima heritage, the diabetic risk allele
(C) of rs1570056 was signiﬁcantly associated with reduced
ASK1 expression (P  0.003, r  0.22, n  153; Fig. 2).
Furthermore, among 116 of these nondiabetic subjects
who had undergone the hyperinsulinemic clamp at the
time of their biopsy, ASK1 expression levels were posi-
tively correlated with in vivo insulin action (P  0.02, r 
0.23, adjusted for age, sex, percent body fat, and Pima
heritage; Fig. 3).
DISCUSSION
Although insulin resistance is a predominant clinical fea-
ture of type 2 diabetes, most of the type 2 diabetes risk loci
identiﬁed in prior GWASs appear to affect insulin secre-
tion, but not insulin sensitivity (16). A key ﬁnding of the
present study is that variations in ASK1 (tagged by
rs1570056 in Pima Indians) increase risk for both in vivo
insulin resistance and type 2 diabetes, where the risk
alleles are further associated with reduced ASK1 expres-
sion in skeletal muscle and lower ASK1 expression levels
are correlated with reduced insulin sensitivity in vivo. It
remains unclear why rs1570056 was associated with type 2
diabetes in the initial population-based sample of full-
heritage Pima Indians and the DIAGRAM Caucasians but
not the second population-based sample of Native Ameri-
cans that included mixed-heritage individuals. However,
the summary estimate of the odds ratio from both Pima
groups and from DIAGRAM was 1.07, and the power of the
second population sample is modest for effects of this
magnitude, even with 3,700 individuals genotyped. We
estimate the power of this second sample to detect an
odds ratio of 1.07 given the allele frequency of 0.32 is 	20%
at P  0.05 (17). The association for type 2 diabetes did not
reach genome-wide signiﬁcance (P  5  10
8) even in the
combined analysis; however, the associations with mea-
sures of insulin action and with expression levels suggest
that these genetic effects are biologically meaningful,
despite the lack of genome-wide signiﬁcance. The role of
rs35898099, which was associated with type 2 diabetes in
both the full-heritage Pima Indian and Native American
samples, but was not associated with ASK1 expression,
deserves further investigation in other ethnic groups.
Our expression study in skeletal muscle showed the
insulin resistance risk allele of rs1570056 was associated
with reduced ASK1 expression and the lower expression
level of ASK1 predicted decreased in vivo insulin action.
This ﬁnding is consistent with Yang et al. (18), who found
that ASK1 (also known as MAP3K5) expression in human
subcutaneous adipose tissue was positively correlated
with in vivo glucose disposal rate. Moreover, they also
found the ASK1 expression was inversely associated with
adipose cell mass. Our expression study in skeletal muscle
did show a negative correlation of the ASK1 expression
with BMI and percent body fat (adjusted P  0.004 and
0.006, r  0.23 and 0.22, for BMI and percent body fat,
respectively; supplementary Fig. 1). Furthermore, we per-
formed real-time PCR for ASK1 in subcutaneous adipo-
cytes isolated from 77 nondiabetic Pima Indians and
conﬁrmed the negative correlation between BMI or per-
cent body fat and ASK1 expression (adjusted P  3.6 
10
6 and 3.3  10
7, r  0.50 and 0.54, for BMI and
percent body fat, respectively; supplementary Fig. 2).
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vivo insulin action persisted despite control for adiposity,
this suggests obesity may not fully account for the insulin
resistance caused by lower ASK1 expression.
Skeletal muscle and adipose tissues are two major
insulin-responsive tissues, where insulin increases glucose
uptake not only through stimulating GLUT4 translocation
to the cell surface but also by increasing the intrinsic
activity of GLUT4 (19). As the highest module of MAP
kinase cascade, ASK1 may inﬂuence both translocation
and activation of GLUT4 by activating its downstream
MAP2K4/MAP2K7-JNK and MAP2K3/MAP2K6-p38 path-
ways (20). GLUT4 translocation is regulated by the IRS1-
PI3K-Akt signaling pathway (21). JNK activation has been
suggested to impair insulin signaling by decreasing insulin-
stimulated tyrosine phosphorylation of IRS1 (22). Imoto et
al. (23) reported that over-activation of ASK1 in human
hepatoma cells impaired insulin signaling and partly me-
diated tumor necrosis factor (TNF)-
–induced insulin
resistance by activating JNK. In this case, reduced ASK1
expression seems likely to promote GLUT4 translocation
and improve insulin sensitivity. This hypothesis is not
supported by our ﬁndings. However, the report by Imoto et
al. was based on a hepatoma cell study and thus may not
represent what happens in muscle or fat cells in vivo. On
the other hand, although GLUT4 translocation is a prereq-
uisite for insulin action in muscle and fat tissue (24,25),
evidence suggests that insulin-stimulated glucose trans-
port still needs the activation of GLUT4 (26–28). The
activation of p38 MAPK is thought to be involved in the
insulin-induced enhancement of intrinsic GLUT4 activity
(28–32). For instance, inhibition of p38 by diverse inhibi-
tors suppresses glucose transport but not GLUT4 translo-
cation in both mouse adipocytes and myotubes (28–31). In
contrast, activation of p38 by a speciﬁc activator stimu-
lates p38 phosphorylation and increases glucose transport
in skeletal muscle cells (32). In this aspect, reduced ASK1
expression may decrease the phosphorylation and inhibit
TABLE 3
Associations of rs1570056 (C/T) with diabetes-related traits in the nondiabetic Native Americans who had been metabolically
phenotyped
Phenotype
CC CT TT P
Female/male (n) 24/29 73/98 113/169
Age (years) 27  0.9 27  0.5 27  0.4
Percent body fat*†‡§ 32.3  1.2 31.8  0.6 32.2  0.5 0.67
BMI (kg/m
2)*†‡§ 32.6  0.8 32.6  0.5 33.3  0.4 0.53
Fasting plasma glucose (mg/dl)*†‡§ 89.1  1.4 88.3  0.7 89.0  0.6 0.59
2-h plasma glucose (mg/dl)*†‡§ 131.8  4.2 121.1  2.4 121.0  1.8 0.07
Log10 fasting plasma insulin (U/ml)*†‡§ 1.60  0.03 1.53  0.02 1.54  0.01 0.04
Log10 2-h plasma insulin (U/ml)*†‡§ 2.26  0.04 2.17  0.03 2.15  0.02 0.04
Endogenous glucose production basally (mg 
kg EMBS
1  min
1)*†‡§ 1.91  0.03 1.89  0.02 1.91  0.01 0.66
Log10 insulin-stimulated glucose disposal (mg 
kg EMBS
1  min
1)*†‡§ 0.52  0.02 0.57  0.01 0.56  0.01 0.02
Endogenous glucose production during the clamp
(mg  kg EMBS
1  min
1)*†‡§ 0.39  0.05 0.30  0.03 0.38  0.02 0.64
Log10 acute insulin response (U/ml)*†‡¶ 2.30  0.09 (n  19) 2.32  0.03 (n  85) 2.36  0.02 (n  174) 0.48
Data are raw (unadjusted) means  SE. P values are given for an additive model and are adjusted for the covariates as indicated: *age, †sex,
‡family membership, §Pima heritage, percent body fat, and ¶insulin-stimulated glucose disposal rate. The analysis of acute insulin response
was restricted to 278 full-heritage Pima Indians who were normal glucose tolerant, and the number of the subjects for each genotypic group
is shown in the corresponding parentheses. The diabetic risk allele (C) is shown in italics. EMBS, estimated metabolic body size.
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at least on skeletal muscle cell surface. This hypothesis is
in agreement with the positive correlation between ASK1
expression and insulin action observed in our study,
suggesting ASK1 may inﬂuence insulin action in skeletal
muscle mainly through the effect on the p38 MAP kinase
pathway rather than on the JNK pathway.
The region of LD tagged by rs1570056 is large and spans
the ASK1 promoter through intron 5, making it is difﬁcult
to determine the causative variant(s) underlying these
associations. Based on sequence inspection, one potential
causative variant was rs5880308, a short tandem repeat
variant in the core promoter region of ASK1 that was
predicted to affect a TFIIB binding site (MapInspector at
www.genomatix.de). However, we conducted a luciferase
assay that did not show any signiﬁcant difference in
reporter gene activity between the two constructs carrying
different alleles (data not shown), suggesting that this
variant is not functional. These results are consistent with
the study of Arning et al. (33). Thus, additional functional
studies are required to determine the true causative vari-
ant that affects the ASK1 expression.
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